- SQI Diagnostics (SQD) testing partner, KSL Diagnostics has received conditional approval for the EXACT COVID-19 Antibody Test
- SQI Diagnostics CEO Andrew Morris sat down with Shoran Devi to discuss the news
- The EXACT COVID-19 Antibody Test can detect an immune response in both vaccinated and previously COVID-19 infected people
- SQI Diagnostics Inc is a Canada-based company engaged in developing and commercializing proprietary technologies & products for multiplexing diagnostics
- SQI Diagnostics is up 2.86 per cent on the day trading at C$0.18 at 11:30 am EST
SQI Diagnostics (SQD) partner, KSL Diagnostics has received conditional approval from the New York State Department of Health for the EXACT COVID-19 Antibody Test.
Access to the EXACT COVID-19 Antibody Test will now be available to physicians and their patients in the United States through AZOVA Inc.
SQI Diagnostics CEO Andrew Morris sat down with Shoran Devi to discuss the news.
“The EXACT COVID-19 Antibody Test is the next generation of tools in the fight against COVID-19. It gives peace of mind because it can detect an immune response in both vaccinated and previously COVID-19 infected people. It also has the potential to give the health care system key insights and data into the relationship between antibody levels and breakthrough infections and reinfections. We’re bringing these tests to market now because we are determined to do our part to end the pandemic.”
SQI Diagnostics is a Canada-based company engaged in developing and commercializing proprietary technologies & products for multiplexing diagnostics.
SQI Diagnostics Inc. (SQD) is up 2.86 per cent on the day trading at C$0.18 at 11:30 am EST.
